Are Peptides Legal in 2026? Where BPC-157, TB-500, MOTS-c and KPV Stand
The rules around peptides changed more in 2026 than in years. Here's where things stand, and why "legal" depends on which question you're asking.
Key takeaways
- "Is it legal?" is really several questions: FDA approval, pharmacy compounding, state rules, travel and import, and anti-doping.
- BPC-157, TB-500, MOTS-c and KPV aren't FDA-approved drugs.
- Several were removed from FDA's compounding "safety risk" category after their nominations were withdrawn; FDA now lists them as "nominated but withdrawn".
- In July 2026, an FDA advisory committee voted in favor of several for possible compounding eligibility. Those votes are advisory, and FDA hasn't acted.
- All four statuses can change. This page is dated and updated when they do.
"Are peptides legal?" is one of the most searched questions in this space, and most answers online are either out of date or oversimplified. This guide separates the questions and gives the status as of October 2026.
Five different questions
| Question | Who decides | Where things stand for BPC-157, TB-500, MOTS-c, KPV |
|---|---|---|
| Is it an approved drug? | FDA | No |
| Can pharmacies compound it? | FDA, under federal compounding rules | Unresolved; under review after a July 2026 advisory vote [2] |
| Can a provider prescribe or dispense it? | Federal and state rules | Depends on the substance and the state |
| Can I travel with it or import it? | Customs and the destination country | Varies by country; see Traveling With Peptides |
| Is it allowed in sport? | WADA, USADA and governing bodies | BPC-157, TB-500 and MOTS-c are prohibited at all times [3] |
FDA approval
An FDA-approved drug has been reviewed for safety and effectiveness for a specific use. None of these four peptides has been approved for any use. A clinician recommending one, or a device being listed with FDA, doesn't change that. For more, read Are Peptide Patches FDA Approved?
Compounding: what changed in 2026
- 2023: FDA placed BPC-157, TB-500 and other peptides in Category 2 of its interim list of bulk substances, the group FDA identified as potentially presenting significant safety risks in compounding.
- April 2026: the nominations for these peptides were withdrawn. FDA's page, updated April 22, 2026, now lists BPC-157, the TB-500 fragment, MOTS-c and KPV in a separate "nominated but withdrawn" table, which still notes potential risks such as immune reactions and impurities [1].
- July 23–24, 2026: FDA's Pharmacy Compounding Advisory Committee reviewed several peptides and voted in favor of BPC-157, KPV, TB-500 and MOTS-c, among others, for possible inclusion on the list of substances pharmacies may compound [2].
- Now: advisory votes are recommendations. FDA makes the final decision through formal rulemaking, which hasn't happened yet. Until it does, these peptides aren't on the approved compounding list.
State rules
State pharmacy and medical boards can add their own requirements, and some have issued notices about peptides. Rules vary, so there's no single 50-state answer. If you're a provider, check your state board's current guidance.
Sport
Anti-doping rules apply regardless of legality. BPC-157, TB-500 and MOTS-c are prohibited at all times under the WADA Prohibited List. See Peptides and Drug Testing.
Where LavION fits
LavION's formulas aren't FDA-approved drugs, and statements about them haven't been evaluated by FDA. LavION sells finished, labeled patches with disclosed amounts and independently tested ingredient lots, and requires a Good Faith Exam with a licensed provider before first purchase. That's about quality and oversight. It isn't FDA approval.
This page is dated. Status as of October 2026. We'll update it when FDA acts on the July 2026 recommendations. This article is general information, not legal advice.
References
- 1.U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (page updated April 22, 2026). fda.gov
- 2.U.S. Food and Drug Administration. July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- 3.World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026 (in force January 1, 2026). wada-ama.org
Frequently asked questions
Is BPC-157 legal?
A yes-or-no answer is misleading. BPC-157 isn't an FDA-approved drug, its compounding status is under review after a July 2026 advisory vote, and it's prohibited in tested sport. Rules on possession and prescribing vary.
Is BPC-157 banned by the FDA?
"Banned" isn't quite the right word. It was placed in FDA's compounding safety-risk category in 2023, the nomination was withdrawn in 2026, and an advisory committee voted in favor of it in July 2026. FDA hasn't made a final decision.
Is TB-500 FDA approved?
No.
Is MOTS-c FDA approved?
No.
What happened at the July 2026 FDA meeting?
FDA's Pharmacy Compounding Advisory Committee voted in favor of several peptides, including BPC-157, KPV, TB-500 and MOTS-c, for possible compounding eligibility. The votes are advisory; FDA decides through formal rulemaking.
Does legal mean allowed in sport?
No. Anti-doping rules apply separately. BPC-157, TB-500 and MOTS-c are prohibited at all times.
Keep reading
This article offers general wellness education and does not replace medical advice. Statements about LavION products have not been evaluated by the FDA, and these products are not intended to diagnose, treat, cure, or prevent disease. Peptide orders include a clinician review before fulfillment. If you are pregnant, nursing, managing a condition, or taking medication, speak with your clinician. See our medical disclaimer.